Targeting the epigenome in malignant pleural mesothelioma
Translational Lung Cancer Research 2017 June [Link]
McLoughlin KC, Kaufman AS, Schrump DS
Malignant pleural mesotheliomas (MPM) are notoriously refractory to conventional treatment modalities. Recent insights regarding epigenetic alterations in MPM provide the preclinical rationale for the evaluation of novel combinatorial regimens targeting the epigenome in these neoplasms.